Tech Company Financing Transactions
Noema Pharma Funding Round
Forbion Capital Partners and Jeito Capital joined a $112 million Series B funding round for Noema Pharma. The round was announced on 3/7/2023.
Transaction Overview
Company Name
Announced On
3/7/2023
Transaction Type
Venture Equity
Amount
$112,000,000
Round
Series B
Investors
Forbion Capital Partners (Lead Investor) (Nanna Lüneborg)
Jeito Capital (Lead Investor) (Rachel Mears)
Proceeds Purpose
The proceeds of the Series B financing will be used to advance Noema Pharma's clinical-stage assets including its lead compound basimglurant (NOE-101), an mGluR5 inhibitor which is being evaluated in Phase 2b clinical trials for severe pain in Trigeminal Neuralgia (TN) and seizures in Tuberous Sclerosis Complex (TSC).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Barfüsserplatz 3
Basel, 4051
CH
Basel, 4051
CH
Phone
Undisclosed
Website
Email Address
Overview
Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema's research and development is focused on understanding and meeting patient needs using our novel therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
George Garibaldi
Chief Financial Officer
Michael Gutch
Co-Founder
Luigi Costa
Browse more venture capital transactions:
Prev: 3/6/2023: SteadyPay venture capital transaction
Next: 3/7/2023: Tensor venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs